Trigeminal neuralgia (TGN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve. Carbamazepine (Tegretol, generics) is the only therapy formally approved for the treatment of TGN in the United States, but its use is limited by safety and tolerability concerns. Therefore, TGN patients may be managed by a variety of off-label medications along their treatment journey, including oxcarbazepine (Supernus’s Oxtellar XR, generics), other antiepileptics, gabapentin (Neurontin, generics), opioid analgesics, and even neuromuscular blocking agents (Allergan’s Botox). However, a substantial portion of TGN patients are treatment refractory, and better treatment options for these patients are needed.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Pfizer, Allergan
Key drugs: Carbamazepine/ carbamazepine XR, oxcarbazepine, gabapentin, Lyrica, opioid analgesics, Botox, other antiepileptics
Key analysis provided: